In a patient who is nil per os (NPO) for a wound debridement procedure, alert (GCS 15) with no neurologic deficits and on levetiracetam for seizure prophylaxis, should the levetiracetam be continued and how should it be administered?

Should Levetiracetam Be Continued When NPO for Surgery?

Yes, levetiracetam should absolutely be continued when a patient is NPO for a procedure, administered intravenously at the equivalent dose and frequency of the oral regimen. Missing doses of antiseizure medication can precipitate breakthrough seizures, which could have been prevented by switching to IV administration.

Key Recommendation

According to the FDA label for levetiracetam, when switching from oral to intravenous dosing, the initial total daily intravenous dosage should be equivalent to the total daily dosage and frequency of oral levetiracetam 1. The IV formulation is specifically indicated for adult patients when oral administration is temporarily not feasible 1.

Administration Details

• Route: Administer as IV infusion over 15 minutes 1
• Dosing: Maintain the same total daily dose and frequency as the oral regimen
• No dilution needed: Levetiracetam in Sodium Chloride Injection should not be further diluted prior to use 1
• Available concentrations: 500 mg, 1000 mg, or 1500 mg in 100 mL bags 1

Critical Rationale

Risk of Withdrawal Seizures

Levetiracetam should be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus 1. Missing even a single dose during an NPO period creates an unnecessary gap in seizure prophylaxis or treatment that could lead to:

• Breakthrough seizures
• Status epilepticus
• Increased morbidity and potential mortality

Seamless Transition Protocol

The FDA label explicitly addresses this scenario with clear guidance 1:

1. Before procedure: Continue oral dosing until NPO status begins
2. During NPO period: Switch to IV at equivalent dose/frequency
3. After procedure: Resume oral administration at the equivalent daily dosage and frequency of the IV administration 1

Practical Implementation

For a patient on levetiracetam 500 mg twice daily orally:

• NPO transition: Give levetiracetam 500 mg IV every 12 hours
• Timing: Ensure the IV dose is given at the scheduled time, even if the patient is NPO
• Post-procedure: Resume oral 500 mg twice daily once able to take PO

For a patient on 1000 mg twice daily:

• NPO transition: Give levetiracetam 1000 mg IV every 12 hours
• Continue this regimen throughout the NPO period

Common Pitfalls to Avoid

1. Do NOT hold antiseizure medications simply because the patient is NPO - this is a preventable medication error
2. Do NOT wait until after the procedure to address missed doses - proactive conversion prevents seizures
3. Do NOT reduce the dose when converting to IV - maintain therapeutic levels with equivalent dosing
4. Ensure coordination between surgical and pharmacy teams so IV doses are available and administered on schedule

Special Considerations

• Renal function: If the patient has impaired renal function, dosing adjustments should already be in place and should be maintained with IV administration 1
• Timing of surgery: Coordinate with anesthesia to ensure the patient receives their scheduled dose, even in the preoperative holding area if necessary
• Documentation: Clearly document the conversion to IV and back to PO to prevent dosing errors during transitions of care

This approach prioritizes patient safety by maintaining consistent antiseizure medication levels, preventing the morbidity associated with breakthrough seizures, and ensuring quality of life is not compromised by a preventable adverse event.